TGF-β1-induced apoptosis in retinal endothelial cells is implicated in retinal vein occlusion

Fengyu Chen1, Qi Wang1, Yujin Li1

  • 1Department of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Yunnan Province Clinical Center for Hematologic Disease, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, Kunming, Yunnan, China; Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.

Experimental Eye Research
|November 22, 2024
PubMed

Insights

Transforming retinal vein occlusion (RVO) treatment, this study reveals transforming growth factor-beta 1 (TGF-β1) as a key driver of retinal endothelial cell apoptosis. Inhibiting the TGF-β1 pathway offers a promising therapeutic strategy for RVO.

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Molecular Medicine

Background:

  • Retinal vein occlusion (RVO) causes vision loss via retinal endothelial cell injury and apoptosis.
  • Identifying molecular pathways is crucial for developing effective RVO therapies.

Purpose of the Study:

  • To identify key molecular pathways and therapeutic targets in RVO pathogenesis.
  • To investigate the role of TGF-β1 in RVO-induced endothelial cell apoptosis.

Main Methods:

  • Transcriptomic analysis in a mouse RVO model.
  • In vitro studies using human retinal microvascular endothelial cells (HRMECs) subjected to oxygen-glucose deprivation/reperfusion (OGD/R) and UV exposure.
  • Assays for gene expression, protein levels, apoptosis, and reactive oxygen species (ROS).

Main Results:

  • 392 differentially expressed genes were identified, enriched in MAPK and TGF-β signaling pathways.
  • TGF-β1 expression and signaling (pSmad2/3) increased in HRMECs after OGD/R or UV exposure.
  • TGF-β1 mediated apoptosis via p38/JNK activation, and its inhibition reduced apoptosis and oxidative stress.

Conclusions:

  • TGF-β1 is a critical mediator of retinal endothelial injury in RVO through p38/JNK-induced apoptosis.
  • Inhibiting the TGF-β1 pathway presents a potential therapeutic strategy for RVO.
  • This research provides novel insights into RVO pathogenesis and treatment targets.